Cue Biopharma (CUE) AI Stock Analysis

• Market Cap: $52.38M
• Dividend Yield: N/A
• Average Volume (3M): 263.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: 13.83%
• EPS Growth: 37.66%
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.17
• Shares Outstanding: 75,349,884
• 10 Day Avg. Volume: 459,009
• 30 Day Avg. Volume: 263,907
• PEG Ratio: -0.39
• Price to Book (P/B): 1.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.42
• Enterprise Value/Market Cap: 1.32
• Enterprise Value/Revenue: 1.97
• Enterprise Value/Gross Profit: -45.03
• Enterprise Value/Ebitda: -0.44
• 1Y Price Target: $2.00
• Price Target Upside: 185.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 50 Neutral
• Price Target: $0.50 ▼(-28.57%Downside)

Cue Biopharma faces significant financial challenges with negative profitability and cash flow issues being major concerns. The technical outlook is neutral, and valuation metrics suggest undervaluation risks. However, recent corporate developments and positive analyst sentiment offer some optimism, balancing the overall score.

Positive Factors

Partnership and Collaborations

With a potential partnership upcoming for CUE-501 and a cash position of $22.5MM, Cue remains an attractive investment opportunity with upside potential if a partnership materializes.

Product Development

Cue regained the global rights for CUE-401 from Ono and expects to submit an IND, indicating progress in their product development pipeline.

Negative Factors

Clinical Development Challenges

The presence of confounding variables and lack of a partner may hinder the clinical development progress of CUE-101.

Program Deprioritization

The company has deprioritized its oncology programs, which may impact its current focus and resources.

Cue Biopharma Business Overview & Revenue Model

Company Description

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Cue Biopharma generates revenue primarily through strategic collaborations and licensing agreements with larger pharmaceutical and biotechnology companies. Through these partnerships, Cue Biopharma receives upfront payments, research funding, and milestone payments based on the achievement of specific development and regulatory goals. Additionally, if the partnered therapies successfully reach the market, the company may earn royalties on sales. These collaborations are crucial for funding continued research and development activities, as the company currently does not have any products approved for commercial sale. Other potential revenue sources include government grants and funding from research institutions that support the advancement of Cue Biopharma's technologies and therapeutic candidates.

Cue Biopharma Financial Statement Overview

Summary

Cue Biopharma faces significant financial challenges, characterized by negative profitability margins and cash flow deficits. While there are some positive aspects, such as past revenue growth and cash reserves, the company must improve its operational efficiency and find ways to achieve consistent profitability to improve its financial health.

Income Statement

Cue Biopharma's revenue has been inconsistent, with a significant drop from $9.3M in 2024 to $7.99M in TTM. The gross profit margin is negative, indicating costs are exceeding revenues. The net profit margin is also deeply negative, reflecting ongoing profitability challenges. Despite these issues, the revenue growth from 2022 to 2024 shows potential for improvement.

Balance Sheet

The company maintains a reasonable debt-to-equity ratio, although the declining stockholders' equity is concerning. The equity ratio has also decreased, suggesting higher leverage and potential risk. However, the company still holds a substantial amount of cash relative to its liabilities, which could provide some stability.

Cash Flow

Cue Biopharma is experiencing negative free cash flow, with little growth in operating cash flow to net income ratio. The consistent negative operating cash flow indicates that the company is not generating enough cash to sustain its operations without financing, which poses a risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.99M	9.29M	5.49M	1.25M	14.94M	3.15M
Gross Profit	-1.54M	9.29M	-32.61M	-560.83K	16.72M	-30.39M
EBITDA	-37.27M	-37.53M	-46.05M	-50.49M	-45.44M	-43.99M
Net Income	-40.58M	-40.67M	-50.73M	-52.80M	-44.16M	-44.78M
Balance Sheet
Total Assets	22.25M	32.19M	61.53M	91.28M	83.40M	99.53M
Cash, Cash Equivalents and Short-Term Investments	13.14M	22.46M	48.51M	76.29M	64.37M	84.87M
Total Debt	7.13M	8.88M	14.70M	19.32M	10.05M	7.15M
Total Liabilities	15.67M	14.69M	24.45M	25.60M	17.91M	20.62M
Stockholders Equity	6.58M	17.50M	37.09M	65.68M	65.49M	78.91M
Cash Flow
Free Cash Flow	-34.88M	-36.40M	-39.96M	-41.98M	-39.75M	-33.09M
Operating Cash Flow	-34.72M	-36.33M	-39.96M	-41.81M	-38.84M	-32.49M
Investing Cash Flow	-63.00K	32.00K	25.00M	-24.61M	9.11M	4.46M
Financing Cash Flow	6.89M	10.24M	11.86M	53.66M	19.23M	58.61M

Cue Biopharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CUE, the sentiment is Neutral. The current price of 0.7 is above the 20-day moving average (MA) of 0.67, below the 50-day MA of 0.70, and below the 200-day MA of 1.03, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.63 is Neutral, neither overbought nor oversold. The STOCH value of 30.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CUE.

Cue Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	68 Neutral	$393.86M	5.04	-58.97%	―	23.81%	146.45%
Sector *	52 Neutral	$7.53B	0.32	-61.76%	2.28%	16.60%	1.56%
CUE	50 Neutral	$52.38M	―	-221.66%	―	13.83%	37.66%
PDSB	50 Neutral	$60.79M	―	-119.22%	―	―	25.51%
MAIA	44 Neutral	$56.07M	―	-1131.02%	―	―	23.55%
PYPD	41 Neutral	$35.67M	―	-853.05%	―	―	34.97%
STRO	38 Underperform	$64.46M	―	-679.15%	―	-56.88%	-57.57%

Cue Biopharma Corporate Events

Cue Biopharma Amends License Agreement with MIL 40G

On June 30, 2025, Cue Biopharma, Inc. and MIL 40G, LLC amended their License Agreement, resulting in a reduced monthly rental rate from $235,883.98 to $147,545.69, effective immediately, with a 4% increase scheduled for April 15, 2027. Additionally, the agreement’s term was extended to April 14, 2028, and Cue Biopharma received a partial rent credit for June 2025, potentially improving its financial standing and operational flexibility.

The most recent analyst rating on (CUE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.

Cue Biopharma CFO Resignation and Board Appointment

On June 4, 2025, Cue Biopharma, Inc. appointed Jill Broadfoot to its board of directors, where she will serve as Chair of the Audit Committee. Additionally, the company’s stockholders approved the 2025 Stock Incentive Plan during the annual meeting. On the same day, Kerri-Ann Millar announced her resignation as Chief Financial Officer, effective June 13, 2025, with CEO Daniel R. Passeri stepping in as interim CFO. Furthermore, the company filed a Certificate of Amendment to increase its authorized shares of capital and common stock, reflecting strategic growth initiatives.

The most recent analyst rating on (CUE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.